Table 3 Adverse events of grade 3 or higher during anti-PD-1/TA treatment
Event | anti-PD-1/TA alone (N = 32) | anti-PD-1/TA + SBRT (N = 42) |
|---|---|---|
No. of patients (%) | ||
Any adverse event of grade 3 or 4 | 21 (65.6) | 23 (54.8) |
Hypertension | 4 (12.5) | 5 (11.9) |
Fatigue | 4 (12.5) | 7 (16.7) |
Proteinuria | 5 (15.6) | 1 (2.4) |
Diarrhea | 3 (9.4) | 4 (9.5) |
Vomiting | 1 (3.1) | 1 (2.4) |
Colonic obstruction | 0 (0) | 1 (2.4) |
Gastric perforation | 1 (3.1) | 0 (0) |
Hoarseness | 1 (3.1) | 0 (0) |
Hypothyroidism | 1 (3.1) | 0 (0) |
Creatinine increased | 2 (4.8) | 1 (2.4) |
Neutrophil count decreased | 1 (3.1) | 1 (2.4) |
Anemia | 3 (9.4) | 6 (14.3) |
Palmar–plantar erythrodysesthesia syndrome | 3 (9.4) | 2 (4.8) |
Pneumonitis | 2 (4.8) | 1 (2.4) |
Maculopapular rash | 1 (3.1) | 2 (4.8) |